• PDF / 169,360 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 96 Downloads / 141 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 4 case reports In a retrospective study conducted between 2004 and 2018, four patients [ages and sexes not stated] were described, who developed sinusoidal obstruction syndrome, autoimmune neutropenia, pure red blood cell aplasia or autoimmune myositis while receiving myeloablative conditioning therapy with busulfan, fludarabine and alemtuzumab [not all dosages and routes stated; durations of treatments to reactions onset not stated]. The patients received myeloablative conditioning regimen including busulfan, fludarabine and IV alemtuzumab 0.5 mg/kg prior to nonmalignant haematopoietic cell transplant. Subsequently, the patients developed toxicities including sinusoidal obstruction syndrome (n=1), autoimmune neutropenia (n=1), pure red blood cell aplasia (n=1) and autoimmune myositis (n=1) while receiving myeloablative conditioning regimen. The patient, who developed sinusoidal obstruction syndrome, was treated with supportive therapy. Following supportive therapy, sinusoidal obstruction syndrome resolved [not all outcomes stated]. Contreras CF, et al. Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants. Biology of Blood and Marrow Transplantation 26: 1646-1654, No. 9, 803517496 Sep 2020. Available from: URL: http://doi.org/10.1016/j.bbmt.2020.06.004

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832